Biomarin Pharmaceutical Inc., of San Rafael, Calif., selected a new drug development candidate, BMN 250, a fusion of alpha-N-acetyglucosaminidase with a peptide derived from insulin-like growth factor 2 for the treatment of Sanfilippo B syndrome or Mucopolysaccharidosis type IIIB.